CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 812,733	$ 535,203
Marketable securities	596,847	503,481
Accounts receivable - trade, net	1,538,642	1,343,368
Accounts receivable from Sanofi	193,684	92,989
Accounts receivable from Bayer	242,014	175,263
Inventories	726,138	399,356
Prepaid expenses and other current assets	224,972	130,528
Total current assets	4,335,030	3,180,188
Marketable securities	1,486,494	864,260
Property, plant, and equipment, net	2,358,605	2,083,421
Deferred tax assets	506,291	825,303
Other assets	77,866	20,294
Total assets	8,764,286	6,973,466
Current liabilities:
Accounts payable and accrued expenses	815,078	879,096
Capital and facility lease obligations	0	129,557
Deferred revenue from Sanofi, current portion	177,746	115,267
Deferred revenue - other, current portion	142,392	116,397
Other current liabilities	267	1,178
Total current liabilities	1,135,483	1,241,495
Capital and facility lease obligations, noncurrent	703,453	351,569
Deferred revenue from Sanofi	379,936	503,474
Deferred revenue - other	249,263	327,298
Other long term liabilities	152,073	100,385
Total liabilities	2,620,208	2,524,221
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,512,833	3,029,993
Retained earnings	2,946,733	1,748,222
Accumulated other comprehensive (loss) income	640	(12,840)
Treasury Stock	(316,240)	(316,240)
Total stockholders' equity	6,144,078	4,449,245
Total liabilities and stockholders' equity	8,764,286	6,973,466
Class A Stock
Stockholders' equity:
Common stock	2	2
Total stockholders' equity	2	2
Common Stock
Stockholders' equity:
Common stock	110	108
Total stockholders' equity	$ 110	$ 108